Hall, Andrew Brantley
Yassour, Moran
Sauk, Jenny
Garner, Ashley
Jiang, Xiaofang
Arthur, Timothy
Lagoudas, Georgia K.
Vatanen, Tommi
Fornelos, Nadine
Wilson, Robin
Bertha, Madeline
Cohen, Melissa
Garber, John
Khalili, Hamed
Gevers, Dirk
Ananthakrishnan, Ashwin N.
Kugathasan, Subra
Lander, Eric S.
Blainey, Paul
Vlamakis, Hera
Xavier, Ramnik J.
Huttenhower, Curtis https://orcid.org/0000-0002-1110-0096
Funding for this research was provided by:
National Institutes of Health (U54DE023798)
National Science Foundation (MCB-1453942)
Crohn's and Colitis Foundation of America
Helen Hay Whitney Foundation
Charles A. King Trust
Klarman Family Foundation
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK92405, P30DK43351)
Article History
Received: 23 June 2017
Accepted: 6 November 2017
First Online: 28 November 2017
Ethics approval and consent to participate
: The design of the study was approved by the Institutional Review Board of Massachusetts General Hospital (protocol number 2004P001067). Written informed consent was obtained for participation in the study, and the study design complies with the Declaration of Helsinki.
: Not applicable.
: DG is employed by the Janssen Human Microbiome Institute. CH is on the Scientific Advisory Board for Seres Therapeutics. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.